Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-HF: Dapagliflozin in HFrEF
NCT03036124Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by AstraZeneca. Started Feb 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03036124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036124.